GAS5 and myeloid sarcoma: Specifically, the presence of GAS5 rs2067079-miR-146a rs2910164 CC + CC and CT + CG genotype combinations conferred protective effects against MS risk, reducing it by approximately 10- and 2.6-fold, respectively (P = 0.0062).